Barinthus Biotherapeutics
Barinthus Biotherapeutics
BRNS
NASDAQ
1.32
USD
15.79%
About
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI).
These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies.
These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 15.1K |
| Three Month Average Volume | 500.9K |
| High Low | |
| Fifty-Two Week High | 5.1 USD |
| Fifty-Two Week Low | 1.18 USD |
| Fifty-Two Week High Date | 06 Nov 2023 |
| Fifty-Two Week Low Date | 23 Aug 2024 |
| Price and Volume | |
| Current Price | 1.315 USD |
| Beta | -1 |
| Relative Price Change | |
| Four Week Relative Price Change | -13.56% |
| Thirteen Week Relative Price Change | -35.67% |
| Twenty-Six Week Relative Price Change | -59.46% |
| Fifty-Two Week Relative Price Change | -46.18% |
| Year-to-Date Relative Price Change | -69.91% |
| Price Change | |
| One Day Price Change | 2.73% |
| Thirteen Week Price Change | -31.15% |
| Twenty-Six Week Price Change | -55.42% |
| Five Day Price Change | 10.50% |
| Fifty-Two Week Price Change | -32.56% |
| Year-to-Date Price Change | -64.36% |
| Month-to-Date Price Change | -11.74% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.83351 USD |
| Book Value Per Share (Most Recent Quarter) | 3.99695 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.86784 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.08496 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.69063 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.02089 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.91075 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.64651 USD |
| Normalized (Last Fiscal Year) | -1.91075 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.91075 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.64651 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.91075 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.64651 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.67694 USD |
| Cash Per Share (Most Recent Quarter) | 3.00564 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.77008 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.49881 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.42009 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -9,541.40% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -10,463.09% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -9,157.98% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -45.00% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 30.02% |
| EPS Change (Trailing Twelve Months) | -13.61% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 0 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -117,774,000 |
| Net Debt (Last Fiscal Year) | -142,090,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 65 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -56,338,000 |
| Free Cash Flow (Trailing Twelve Months) | -55,005,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -30.31% |
| Return on Assets (Trailing Twelve Months) | -29.51% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -34.14% |
| Return on Equity (Trailing Twelve Months) | -34.13% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.98% |
| Return on Investment (Trailing Twelve Months) | -31.56% |
| Return on Investment (5 Year) | -99,999.99% |